基本信息
views: 9
Career Trajectory
Bio
His overarching mission is to translate research from ‘bench to bedside’; to improve understanding of mechanisms that modulate risk vs resilience, and so develop new diagnostic approaches, treatments, and services.
In autism Professor Murphy established the MRC UK AIMS multi centre imaging network – the first in Europe. From this he developed two European Union funded Innovative Medicines Initiatives in autism. The first was called EU-AIMS . The successor to this (EU AIMS-2-TRIALS) (https://www.aims-2-trials.eu/) brings together 48 partners (including academics, charities, autistic individuals and families, regulators and industry) across 14 European countries. The research programme includes a range of studies. These will explore how autism develops, from before birth to adulthood, and how this varies in different people. We will look for biological markers which indicate whether a person has, or may develop, particular characteristics. These markers may help to identify who could ultimately benefit from particular treatments. We will also test treatments. EU AIMS-2-TRIALS links to other groups in North America, South Africa, China, Australia, and Pakistan .
Research Interests
His main interest is in normal brain development, and how abnormalities in this process lead to neurodevelopmental/neuropsychiatric disorders. He supervises PhD Students in
Fetal/neonatal/infant brain development
Brain changes across the lifespan
Risk vs protective mechanisms underpinning the emergence of a variety of neurodevelopmental disorders including autism, ADHD, epilepsy and psychosis. And factors modulating outcome and response to treatment
Disorders of social behaviour in children and adults – e.g. conduct disorder, callous unemotional behaviour, and psychopathy
The impact of specific genetic abnormalities on brain and behaviour
Biomarker discovery and validation.
Treatment trials (including non pharmacological approaches).
Pharmacochallenge studies using brain imaging
In autism Professor Murphy established the MRC UK AIMS multi centre imaging network – the first in Europe. From this he developed two European Union funded Innovative Medicines Initiatives in autism. The first was called EU-AIMS . The successor to this (EU AIMS-2-TRIALS) (https://www.aims-2-trials.eu/) brings together 48 partners (including academics, charities, autistic individuals and families, regulators and industry) across 14 European countries. The research programme includes a range of studies. These will explore how autism develops, from before birth to adulthood, and how this varies in different people. We will look for biological markers which indicate whether a person has, or may develop, particular characteristics. These markers may help to identify who could ultimately benefit from particular treatments. We will also test treatments. EU AIMS-2-TRIALS links to other groups in North America, South Africa, China, Australia, and Pakistan .
Research Interests
His main interest is in normal brain development, and how abnormalities in this process lead to neurodevelopmental/neuropsychiatric disorders. He supervises PhD Students in
Fetal/neonatal/infant brain development
Brain changes across the lifespan
Risk vs protective mechanisms underpinning the emergence of a variety of neurodevelopmental disorders including autism, ADHD, epilepsy and psychosis. And factors modulating outcome and response to treatment
Disorders of social behaviour in children and adults – e.g. conduct disorder, callous unemotional behaviour, and psychopathy
The impact of specific genetic abnormalities on brain and behaviour
Biomarker discovery and validation.
Treatment trials (including non pharmacological approaches).
Pharmacochallenge studies using brain imaging
Research Interests
Papers共 1074 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Louise Emmett,Nathan Papa,Thomas A Hope,Wolfgang Fendler,Jeremie Calais,Irene Burger,Matthias Eiber,Francesco Barbato,Daniel Moon,William Counter,Nikeith John,Alan Xue,Anthony Franklin,James Thompson,Kris Rasiah,Mark Frydenberg,John Yaxley,James Buteau,Shikha Agrawal,Bao Ho,Andrew Nguyen,Victor Liu,Jonathan Lee,Henry Woo,Edward Hsiao,Thomas Sutherland, Elyse Perry,Phillip Stricker,Michael S Hofman,Veeru Kasivisvanathan,Matthew Roberts,Declan Murphy
The Journal of urologyno. 2 (2024): 299-309
Erika L Juarez-Martinez,Arthur-Ervin Avramiea, Pilar Garcés,Joerg F Hipp,Simon-Shlomo Poil,Marina Diachenko, Huib Mansvelder,Emily JH Jones,Luke Mason,Declan Murphy,Eva Loth,Bethany Oakley,Tony Charman, Tobias Banaschewski,Bob Oranje,Jan Buitelaar,Hilgo Bruining, Klaus Linkenkaer-Hansen
crossref(2024)
Journal of clinical pathology (2024)
David C. Chen, Haidar AlSaffar,Henrike Graefen,Sachin Perera, Elio Mazzone,Marlon L. Perera,Nathan Lawrentschuk,Declan G. Murphy
European neuropsychopharmacology (2024): 35-42
Translational andrology and urologyno. 4 (2024): 653-656
Charles Schleifer,Sarah Chang,Carolyn Amir, Kathleen P. O'Hora,Hoki Fung,Leila Kushan-Wells,Eileen Daly,Fabio Di Fabio, Marianna Frascarelli,Maria Gudbrandsen,Wendy R. Kates,Declan Murphy,Lucina Q. Uddin,Kuldeep Kumar,Gil Hoftman,Carrie E. Bearden
Biological Psychiatryno. 10 (2024)
Scientific reportsno. 1 (2024): 14038-14038
Johanna Leyhausen,Tim Schaefer,Caroline Gurr,Lisa M. Berg,Hanna Seelemeyer,Charlotte M. Pretzsch,Eva Loth,Bethany Oakley,Jan K. Buitelaar,Christian F. Beckmann,Dorothea L. Floris,Tony Charman,Thomas Bourgeron,Tobias Banaschewski,Emily J. H. Jones,Julian Tillmann,Chris Chatham,Declan G. Murphy,Christine Ecker
European Urology (2024)
Load More
Author Statistics
#Papers: 1069
#Citation: 48054
H-Index: 108
G-Index: 192
Sociability: 9
Diversity: 0
Activity: 13
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn